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ardiovascular Risk
n Patients With Human
mmunodeficiency Virus Infection
ncomplete Data*
ames H. Stein, MD
adison, Wisconsin
ince the advent of highly active antiretroviral therapy
HAART) in 1996, the death rate from acquired immune
eficiency syndrome (AIDS) in the U.S. has decreased
ramatically. Because of HAART, it is not uncommon to
eet patients who have lived with human immunodefi-
iency virus (HIV) infection for well over two decades.
hortly after its introduction, however, clinicians observed
n increasing prevalence of a lipodystrophic syndrome
mong patients taking HAART that included hyperlipid-
mia, impaired glucose metabolism, and central adiposity
1,2). Although HAART-associated lipodystrophy shares
imilarities with the more common insulin resistance syn-
rome that predisposes patients to coronary artery disease
See page 1117
“Metabolic Syndrome,” MetS), they clearly are different
isease processes. For example, an important component of
AART-associated lipodystrophy is peripheral fat wasting
lipoatrophy), which is not seen in patients with coronary
rtery disease. It also is not clear if HAART-associated
ipodystrophy carries the same cardiovascular risk as MetS.
o complicate cardiovascular risk assessment further, un-
reated HIV infection also has been associated with dysli-
oproteinemia and premature atherosclerosis (1). Thus, the
valuation of cardiovascular risk in patients with HIV
inges upon a complex interplay of direct and indirect
ascular effects of HIV infection, antiretroviral therapy,
ging, and exposure to cardiovascular risk factors.
In the past five years, several cross-sectional and obser-
ational studies have tried to provide clinical and patho-
hysiological insights into these interrelationships. Unfor-
unately, the observational studies that have been published
r reported at meetings have had significant limitations,
ncluding low rates of adverse cardiovascular events, a short
uration of exposure to HAART, and the usual limitations
ssociated with retrospective studies such as nonsystematic
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiovascular Medicine, University of Wisconsin Medical
chool, Madison, Wisconsin. Dr. Stein is the recipient of a research grant fromd
ristol-Myers Squibb. He has served as a consultant to Abbott Labs and is on the
peaker’s Bureau for Merck (not related to HIV treatment).ssessment of cardiovascular risk factors, a lack of medica-
ion compliance data, and problems with ascertainment of
ase status (1,2). Despite these limitations, these studies
with one exception) have suggested that patients with HIV
nfection are at increased cardiovascular risk, and that use of
rotease inhibitors may be especially disadvantageous from
cardiac standpoint. Although two prospective observa-
ional studies also showed increased risk of myocardial
nfarction in patients receiving HAART, they also suffered
rom low cardiovascular event rates, and concerns have been
aised about problems with case ascertainment and
etween-group differences in the duration of HIV infection
2).
Because of these limitations, many investigators have
sed surrogate imaging markers of atherosclerosis to evalu-
te cardiovascular risk. With one exception, these studies
ave demonstrated that use of HAART is associated with
ndothelial dysfunction, but each study was small and
ross-sectional, with attendant biases and limitations. In
hese studies, atherogenic lipoproteins, markers of insulin
esistance, and in some instances markers of virological
ontrol explained part of the differences in endothelial
unction (2). These observations have been corroborated by
tudies demonstrating that protease inhibitors damage en-
othelial cell mitochondrial deoxyribonucleic acid in cul-
ure, impair vasomotor function, and reduce endothelial
itric oxide synthase expression by coronary artery rings
3,4). Several studies also have shown an increased preva-
ence of carotid plaque or intima-media thickness (CIMT)
mong patients receiving protease inhibitors, but they also
ere small and cross-sectional.
The study by van Wijk et al. (5) adds to the growing
iterature suggesting that individuals receiving HAART
ave markers of vascular disease that are associated with
ncreased cardiovascular risk. In this study, individuals on
AART had impaired flow-mediated vasodilation of the
rachial artery, a marker of endothelial dysfunction. This
grees with previous literature, but is not conclusive because
itroglycerin-mediated vasodilation was impaired; making
t unclear if the differences between the groups were due to
ndothelial dysfunction or a non-endothelium-mediated
rocess.
A very interesting and important aspect of this study was
lassifying patients according to the presence of MetS, using
he National Cholesterol Education Adult Treatment Panel
II guidelines. Although this definition was not intended to
e used for patients with lipodystrophy, HIV-infected
atients with MetS had increased levels of apolipoprotein
-100, C-reactive protein, insulin, and 2-h insulin com-
ared with HIV-infected patients without MetS and HIV-
egative controls. These findings suggest that HIV-infected
atients with MetS have markers of insulin resistance and
ncreased cardiovascular risk (5). Indeed, the major strength
f this report is the completeness of imaging and metabolic
ata. A study with this complete a dataset regarding
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March 21, 2006:1124–5 Editorial CommentAART, metabolic risk factors, and cardiovascular imaging
n patients with HIV and control subjects has not been
eported previously, so it is unique in that regard.
The finding that CIMT was greater among HIV-
nfected patients with MetS is consistent with the metabolic
ata provided by the authors. This finding would have been
ore powerful if it had been corroborated by the aortic
ulse wave velocity data; however, the sample size was
elatively small. Also, certain markers of MetS in HIV-
nfected patients did predict increased pulse wave velocity,
uch as blood pressure, 2-h glucose, and fasting insulin,
uggesting that insulin resistance may be involved in the
athophysiology of vascular dysfunction in patients on
AART. It is interesting that markers of inflammation and
iral load were more associated with CIMT than flow-
ediated vasodilation or pulse wave velocity, but these
ssociations are somewhat difficult to interpret in the
bsence of information about the specific antiretroviral
gents used by the subjects, because agents within classes
ave different effects on insulin-glucose metabolism and
ipoproteins (1). Although the imaging data in this study do
ot conclusively demonstrate that MetS, as traditionally
efined, is useful for identifying increased cardiovascular
isk in HIV-infected patients, the metabolic abnormalities
bserved in MetS patients suggest that insulin resistance
ay be involved and that further studies are needed (5).
uture directions. To better understand cardiovascular
isk in patients on HAART, larger, prospective studies are
eeded. The biases inherent in observational and cross-
ectional studies are well known, and their results can be
isleading. In designing prospective studies, longitudinal
ata regarding changes in structural and functional markers
f vascular disease, risk factors, antiretroviral therapy, and
irological control must be considered, as well as the effect
f aging itself.
Two well-designed studies sponsored by the AIDS Clin-
cal Trial Group (ACTG) recently have been completed.
CTG 5152s is a prospective study of 82 HIV-positive,
reatment-naïve patients randomized to receive one of three
AART regimens that would be predicted to have very
ifferent effects on lipids and insulin-glucose metabolism.
s expected, flow-mediated dilation was impaired before
tarting treatment, but improved significantly and to a
imilar degree in each arm after as few as four weeks of
AART (6). Nitroglycerin-mediated vasodilation did not
hange, indicating that use of HAART rapidly improved
ndothelial function and that cardiovascular risk may de-
rease as HIV infection comes under control. ACTG 5078
s a prospective cohort study of 134 subjects recruited intoarefully matched triads based on HIV serostatus, antiret-
oviral therapy, and cardiovascular risk factors. At baseline,
here were no differences in CIMT between the groups of
IV-infected patients (7). Three-year follow-up of changes
n CIMT, risk factors, and virological markers are expected
n early 2006. These studies will help clarify the major
ontributors to cardiovascular risk in patients with HIV
nfection.
onclusions. In regard to cardiovascular risk in patients
ith HIV, we have incomplete data. Compared with the
igh death rate from AIDS in patients with inadequate viral
uppression, cardiovascular event rates are low and control
f viremia, regardless of the treatment strategy, is more
mportant for long-term survival than any increase in
ardiovascular risk that may be related to metabolic changes
ssociated with HAART. Uncontrolled viremia may be
ore of a cardiovascular risk than controlled infection that
esults in hyperlipidemia and insulin resistance. The overall
essage is that obtaining and maintaining virological con-
rol is the overriding concern in patients with HIV infec-
ion. Metabolic and vascular effects secondary to HAART are
econdary considerations, but are worthy of rigorous investiga-
ion, as suggested by the paper by van Wijk et al. (5).
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